Results 241 to 250 of about 255,046 (288)

Intravenous immunoglobulin

Clinical Immunology and Immunopathology, 1986
The development of immunoglobulin preparations suitable for intravenous use that are safe, acceptable, and efficacious represents a major advance in the treatment of immunodeficient patients. Experience in the United States and elsewhere in the world indicates that the benefits of use in patients with well-documented humoral immunodeficiency far ...
openaire   +2 more sources

Phannacokinetics of Intravenous Immunoglobulin in Neonates

Vox Sanguinis, 1989
Abstract. Intravenous immunoglobulin (IVIG) may be a therapeutic adjunct to antibiotic treatment of neonatal infections. We examined the pharmacokinetics and safety of IVIG in human neonates. Thirty neonates with suspected sepsis were randomly assigned either to a treatment (receiving either 250, 500, or 1,000 mg/kg of IVIG plus antibiotics) or ...
L E, Weisman, G W, Fischer, P, Marinelli, V G, Hemming, J R, Pierce, S M, Golden, C C, Peck   +6 more
openaire   +2 more sources

Immunomodulation With Intravenous Immunoglobulin

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1993
Since its introduction over a decade ago for the treatment of primary immunodeficiencies, intravenous immunoglobulin (IVIG) has demonstrated activity in a variety of autoimmune disorders. An understanding of IVIG's immunomodulatory effects provides the rationale for its potential application in the management of autoimmune disorders.
openaire   +2 more sources

Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin

Journal of Clinical Immunology, 1991
The proliferative responses and the immunoglobulin production of peripheral blood mononuclear cells to pokeweed mitogen were dose-dependently suppressed by sulfonated intravenous immunoglobulin (IVIG), polyethylene glycol-treated IVIG, pH 4-treated IVIG, or human gamma-globulin, but they were not or only slightly suppressed by human serum albumin or ...
N, Kondo, T, Ozawa, K, Mushiake, F, Motoyoshi, T, Kameyama, K, Kasahara, H, Kaneko, M, Yamashina, Y, Kato, T, Orii   +9 more
openaire   +2 more sources

Intravenous Immunoglobulins as Therapeutic Agents

Annals of Internal Medicine, 1987
Intravenous immunoglobulins are stable monomeric pooled human IgG preparations for therapeutic use. Three intravenous immunoglobulins licensed in the United States are generally therapeutically equivalent. Intravenous immunoglobulin is the preferred agent for replacement therapy for most patients with primary or secondary antibody immunodeficiency ...
E R, Stiehm, E, Ashida, K S, Kim, D J, Winston, A, Haas, R P, Gale   +5 more
openaire   +2 more sources

Clinical Use of Intravenous Immunoglobulins

Vox Sanguinis, 2000
Prophylaxis and treatment with i.v. immunoglobulins must envisage preparations from normal or hyperimmunised human donors, animals (horses and rabbits) as well as monoclonal and genetically and proteomically engineered chimeric or recombinant antibodies.
U E, Nydegger, P J, Mohacsi, R, Escher, A, Morell   +3 more
openaire   +2 more sources

Human intravenous immunoglobulin therapy

Seminars in Veterinary Medicine and Surgery: Small Animal, 1997
Human intravenous immunoglobulin (hIVIG) is a preparation of normal polyspecific IgG obtained from the plasma of healthy blood donors. Although purified immunoglobulins were initially developed for treatment of primary immunodeficiency syndromes, they have since been documented to be effective in the treatment of some immune-mediated diseases such as ...
J. Catharine, R. Scott-Moncrieff, William J. Reagan   +2 more
openaire   +2 more sources

INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS

The Lancet, 1983
P, Stanley, P, Cole
openaire   +4 more sources

Sepsis and polyspecific intravenous immunoglobulins

Journal of Clinical Apheresis, 1997
The treatment of sepsis with i.v. immunoglobulins (IVIG) is currently regarded as not indicated. Several clinical studies, placebo controlled since 1985, to determine efficacy have failed to prevent fatal outcome, even when IVIG was given at high doses.
openaire   +3 more sources

Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections

Microorganisms, 2021
Maria Sole Chimenti, Paola Triggianese, Roberto Perricone   +2 more
exaly